CD14 and rheumatoid arthritis: Together, exposure of M1–MØ to low-dose MTX has impact on folate pathway and other downstream metabolic and signalling pathways which apparently contribute to a recently described macrophage reprogramming ability of MTX; the latter confers a state of LPS tolerance associated with higher soluble CD14 levels in the plasma of MTX responding RA patients [25].